<DOC>
	<DOCNO>NCT01862003</DOCNO>
	<brief_summary>Recruitment phase I PANTHER trial complete . In phase II , combination AZD8931 FOLFIRI compare FOLFIRI alone , determine efficacy treatment .</brief_summary>
	<brief_title>Phase I/II Trial Antagonism HER GI Cancer</brief_title>
	<detailed_description>PANTHER register phase I/randomised phase II trial patient recurrent metastatic colorectal cancer . The phase II part study randomise , control , 2 arm trial . Patients randomise : receive AZD8931 ( EGFR/ERBB inhibitor ) combination FOLinic acid , Fluorouracil IRInotecan ( FOLFIRI ) , FOLFIR alone ( control group ) . Treatment give two-weekly cycle . Phase II 's primary objective evaluate efficacy AZD8931 plus FOLFIRI alongside FOLFIRI alone use percentage change tumour size baseline 12 week start treatment .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>1 . Histopathological/cytological diagnosis nonresectable , recurrent metastatic colorectal cancer 2 . Tumour wildtype RAS 3 . Measurable disease evaluate RECIST criterion v1.1 4. WHO performance status 0 1 5 . Age ≥ 16 6 . Estimated life expectancy &gt; 3 month 7 . Adequate haematological function : Haemoglobin ≥100 g/L Absolute neutrophil count ≥1.5 x 10^9/L Platelet count ≥100 x 10^9/L 8 . Adequate liver function : Total bilirubin ≤1.5 x upper limit normal ( ULN ) ALT , AST &amp; ALP ≤2.5 x ULN absence note liver metastasis ALT , AST &amp; ALP ≤5 x ULN presence liver metastases 9 . Adequate renal function : Serum creatinine ≤1.5 x ULN Calculated creatinine clearance ≥30 mL/min 10 . Adequate biliary drainage ( patient stent eligible ) 11 . Adequate venous access collection exploratory biological sample 12 . Women childbearing potential must negative pregnancy test prior study entry . Female patient male patient partner childbearing potential must agree use adequate contraception method , must continue 6 month completion chemotherapy 13 . Must able swallow AZD8931 tablets 14 . Capable give write informed consent 15 . The following prior therapy allow : Surgery patient may undergo noncurative operation palliative bypass surgery . Patients previously undergone curative surgery must evidence nonresectable disease relapse Radiotherapy localise disease Prior adjuvant chemotherapy provide complete least 6 month trial entry 1 . Patients undergoing treatment curative intent 2 . Any prior treatment agent target ERBB pathway 3 . Treatment experimental drug within 30 day 5 halflives first dose AZD8931 4 . Previous chemotherapy metastatic disease 5 . Prior treatment anthracyclines mitoxantrone 6 . Current disease condition know interfere absorption , distribution , metabolism excretion drug ( include refractory nausea vomiting , chronic gastrointestinal disease ( e.g . inflammatory bowel disease ) , significant bowel resection ) 7 . History prior malignancy interfere response evaluation ( exception list protocol ) 8 . Evidence severe/uncontrolled systemic disease laboratory find make undesirable patient participate trial 9 . Evidence active uncontrolled infection 10 . Patients clinically significant ascites and/or effusion 11 . Regular use antidiarrhoeal 12 . Pregnant lactate woman 13 . Cardiac condition ( detailed trial protocol ) 14 . Any psychiatric disorder ( e.g . brain metastasis ) likely impact ability give inform consent 15 . Eye condition ( detailed trial protocol ) 16 . Patients chronic skin condition e.g . acne rosacea , psoriasis , severe atopic eczema 17 . Past medical history interstitial lung disease , druginduced interstitial lung disease , radiation pneumonitis require steroid treatment , evidence clinically active interstitial lung disease 18 . History repeat unexplained episode syncope/dizziness 19 . Known hypersensitivity AZD8931 , excipients , drug class 20 . The use drugs/substances know inhibit induce CYP3A4 CYP2D6 , know prolong QT interval , discontinue duration trial treatment 21 . Patients hereditary fructose intolerance</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Metastatic Colorectal cancer</keyword>
	<keyword>Recurrent Colorectal cancer</keyword>
	<keyword>FOLFIRI</keyword>
	<keyword>AZD8931</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>EGFR</keyword>
</DOC>